Effects of esketamine on inflammation and cognitive function in elderly patients with gastrointestinal tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064076

Enrollment

Unknown

Registered

2022-09-26

Start date

2022-09-26

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive function

Interventions

Intervention Group:Esketamine group

Conrol group:normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Age =65, ASA=I; ? Patients undergoing elective gastrointestinal tumor surgery under general anesthesia; ? Volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Suffering from mental illness (including patients with preoperative delirium) or taking antipsychotic drugs; ? Any cerebrovascular accident, such as stroke or transient ischemic attack (TIA), occurred within 3 months; ? Severe abnormal liver and kidney function (severe abnormal liver function, ALT, AST bound bilirubin, total bilirubin value of one of them more than 2 times the upper limit of normal; Cr clearance rate of severe renal dysfunction was less than 30ml/min); (4) Patients with unstable angina pectoris or myocardial infarction within 3 months; ? Blood pressure =180/110mmHg at preoperative visit; ? hyperthyroidism; ? glaucoma patients with high intraocular pressure; ? reoperation within 3 months; ? Join other researchers within 30 days.

Design outcomes

Primary

Measure	Time frame
Moca;IL-1ß,IL-6,TNF-a;NSE?S-100ß?Aß1-42?NCAM?BNDF?S100A8/A9;	—

Secondary

Measure	Time frame
VAS;adverse reaction;	—

Countries

china

Contacts

Public Contactxiaoyan ma

66846396@qq.com13223651919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026